Five big shifts in policy and technology that marketers should worry about in 2015

Five big shifts in policy and technology that marketers should worry about in 2015

"The trouble is that the market is changing much faster than most marketers realize."

Five things for pharma marketers to know: Friday, December 19

Five things for pharma marketers to know: Friday, December 19

Roche strikes out in cancer, Alzheimer's trials; Lilly in pact for fast-acting insulin; Humana revamps formulary.

Pfizer bets on Duchenne MD treatment

Pfizer bets on Duchenne MD treatment

The company moves on three leading contenders in the muscular dystrophy segment with the start of a Phase II trial

OPDP slams print ad in Untitled Letter

OPDP slams print ad in Untitled Letter

The FDA's prescription drug promotion arm wrote that the professional print ad for seizure med Aptiom "misleadingly overstated its efficacy."

Apotex challenges Amgen blockbuster Neulasta

Canadian firm presents FDA with its third biosimilar application.

Merck buys Swiss biotech

The drugmaker announced it will acquire OncoEthix and its oncology candidate OTX015 in a deal worth up to $365 million

Five things for pharma marketers to know: Thursday, December 18

Five things for pharma marketers to know: Thursday, December 18

Shire may bid on NPS Pharmaceuticals; Amgen says cancer drug will cost $178,000; Takeda has a new head of R&D.

Pfizer urges parents to take the pledge against meningitis

Pfizer urges parents to take the pledge against meningitis

Pfizer has kicked off a disease-awareness campaign, "Take Action Against Meningitis," urging parents to discuss vaccinations with their healthcare providers with paralympic snowboarder Amy Purdy.

Court clears the way for Celebrex generics

Court clears the way for Celebrex generics

Ruling voids FDA's take on reissued patents, settling a year of challenges by generic applicants

FDA issues long-awaited plan for electronic labeling

The much hashed-over initiative would require pharma firms to distribute the professional insert electronically.

Lions Health announces 2015 jury presidents

The annual awards show, celebrating creativity in marketing communications, has named Langland's executive creative director and Sudler & Hennessey chief creative officer to lead the jury.

Five things for pharma marketers to know: Wednesday, December 17

Five things for pharma marketers to know: Wednesday, December 17

UCB generic deal falls through; agency hiring could spike in 2015; teenage prescription drug abuse is on the decline.

Latest orphan-drug approval marks 15th this year

Latest orphan-drug approval marks 15th this year

Swiss drugmaker Novartis received an FDA nod for rare disease treatment Signifor LAR Tuesday, as orphan drug approvals reach new heights.

Danica Patrick paces health system marketing drive

The driver on NASCAR and other racing circuits will help challenge consumers to improve their health habits.

Brain cancer candidate touted for melanoma

Studies by Australian company Novogen are said to demonstrate, for the first time, that a drug highly effective against brain cancers has the same high potency against melanoma.

Pfizer brings humor to menopause marketing

Pfizer brings humor to menopause marketing

The new approach shows "The Talk" has a sequel.

Five things for pharma marketers to know: Tuesday, December 16

Five things for pharma marketers to know: Tuesday, December 16

Bayer consolidates OTC creative portfolio; Genentech R&D head steps down; Novartis receives approval for orphan drug.

Genentech drug combo targets advanced melanoma

The treatment reduces risk by half compared to widely used Zelboraf.

Bayer loses cancer drug patent fight in India

Court clears the way for a Nexavar generic from Natco

Sanofi, Regeneron field pre-launch cholesterol IQ poll

Sanofi, Regeneron field pre-launch cholesterol IQ poll

The drugmakers, who have an experimental cholesterol medication in the works, are asking consumers what they know about heart health.

FDA 2014 approvals outpace those of 2013

FDA 2014 approvals outpace those of 2013

The regulator noted in its early 2014 retrospective that it set a high mark for the number of approved rare disease drugs this year, and that insufficient information is the reason many breakthrough status requests get bounced.

Five things for pharma marketers to know: Monday, December 15

Five things for pharma marketers to know: Monday, December 15

United Healthcare tests an all-in-one cancer payment model, Pfizer inks a worldwide commercialization license for a human growth factor hormone, and the Commonwealth Fund grades Medicare as the program nears its 50th.

Five things for pharma marketers to know: Friday, December 12

Five things for pharma marketers to know: Friday, December 12

Judge rules Actavis must keep Alzheimer's drug on the market; Wyeth CEO joins Roche board, dispelling rumors he may be next Sanofi CEO; Two senators propose new FDA designation which would award 15 years of marketing exclusivity.

Antibiotics maker faces hurdles in diversifying beyond flagship drug

Antibiotics maker faces hurdles in diversifying beyond flagship drug

Cubist is re-launching its C.-Diff. antibiotic in an effort to jumpstart sales beyond Cubicin, which contributes most of its product revenue.

Hey Pharma, Here's Why Your Customer Service Shouldn't Suck

Hey Pharma, Here's Why Your Customer Service Shouldn't Suck

"Customer service is more than just a nice-to-have. In this competitive marketplace, it can mean the difference between your brand or someone else's."

Pfizer's Lyrica ineffective at treating chronic back pain: study

Researchers found no difference between Lyrica (pregabalin) and placebo in treating lumbar spinal stenosis.

Sanofi looks to join M&A trend

Interim CEO Serge Weinberg tells a German paper that the company is prepared to buy assets that meet its goal of providing stable, steady growth.

Five things for pharma marketers to know, Thursday, December 11

Five things for pharma marketers to know, Thursday, December 11

Philadelphia Transportation Authority sues Gilead over Sovaldi sticker shock; Digital marketing tactics raise privacy concerns; another patent cliff is on the horizon.

Survey shows doctors, patients want to embrace apps

Survey shows doctors, patients want to embrace apps

The snag: identifying what qualifies as download-worthy.

Merck rolls out new Keytruda data in hard-to-treat group

Merck rolls out new Keytruda data in hard-to-treat group

The drugmaker shared early-trial results for its PD-1 among hard-to-tread triple-negative breast cancer patients and announced an effort to see if the drug can help patients overcome treatment resistance.

FDA plans review of Sandoz's Neupogen biosimilar

As courts sort out lawsuits over two Sandoz biosimilars, the Novartis unit reports a study showing its BLA candidate has similar efficacy to Neupogen.

Pfizer's Celebrex slammed by entry of generics

Mylan, Teva, and Actavis announced generics of the $3 billion arthritis drug.

Five things for pharma marketers to know: Wednesday, December 10

Five things for pharma marketers to know: Wednesday, December 10

Cubist's best-selling product has four of its five patents invalidated; the first biologic of AbbVie's Humira launches in India; Mylan debuts generic Celebrex.

The Simple Solution to America's Complex Health Literacy Problem

The Simple Solution to America's Complex Health Literacy Problem

"We are living in an era of great medical technological innovations. However, this is shifting healthcare back home and expecting patients to understand excessive medical information and follow complex instructions."

Lilly psoriasis drug hits Phase-III endpoint

An investigational JAK inhibitor, baricitinib, bested placebo in moderate to severe plaque psoriasis in a Phase-III trial.

Patients to influence voice of Lemtrada consumer campaign

Patients to influence voice of Lemtrada consumer campaign

Patient advocates lobbied the FDA to approve the MS drug and Sanofi subsidiary Genzyme says their voice will be part of the consumer outreach when DTC rolls out next year.

Five things for pharma marketers to know: Tuesday, December 9

Five things for pharma marketers to know: Tuesday, December 9

WSJ reported FDA advisors failed to disclose pharma financial ties; Novartis axes 200 employees in New Jersey; Takeda retires the Millennium brand.

Indian merger creates fifth-largest generic drugmaker

Sun Pharma buys troubled Ranbaxy and its pipeline of promising follow-ons.

Positive lymphoma trials point to expanded role for immune therapies

Positive lymphoma trials point to expanded role for immune therapies

Merck's Keytruda and BMS's Opdivo reverse tumor growth in Hodgkin's patients studies.

Medical Advertising Hall of Fame taps new members

MAHF 2015 Heritage Ad Awards will be given to campaigns for Bentyl, Hytrin and Navane

AbbVie oncology pipeline continues to show progress

AbbVie oncology pipeline continues to show progress

Early trials of Venetoclax, formerly known as ABT-199, indicate the experimental drug execs consider an oncology cornerstone continues to show promise.

Five things for pharma marketers to know: Monday, December 8

Five things for pharma marketers to know: Monday, December 8

Merck buys up Cubist in an $8.4B deal, a jury sides with AstraZeneca in a generic Nexium lawsuit and the NYT finds a correlation between Genentech payments and Lucentis prescriptions.

A Call to Action for Healthcare Leaders: Why I Choose to Do More (And Why You Should, Too)

A Call to Action for Healthcare Leaders: Why I Choose to Do More (And Why You Should, Too)

"In this era, it requires mobilizing our collective intelligence toward innovation and integration that is meaningful for large populations."

Five things for pharma marketers to know: Friday, December 5

Five things for pharma marketers to know: Friday, December 5

GSK opts to hold onto $1.6 billion portfolio of older drugs; Sanofi upheavals continue with exit of US diabetes sales exec; Takeda gains breakthrough status on AL amyloidosis therapy.

Array gets binimetinib all to itself

Transfer of rights to the experimental cancer drug hinges on completion of Novartis/GSK asset swap.

Millennials don't care about traditional healthcare: study

Millennials don't care about traditional healthcare: study

Members of the 13-32 age group were less likely to agree that preventive care is the most important factor in staying healthy, compared to Baby Boomers and Gen-Xers.

Incyte drug gains expanded indication for bone marrow disease

Jakafi becomes the first drug approved for treating polycythemia vera.

GSK shrinks, and respiratory looks set to stumble

GSK shrinks, and respiratory looks set to stumble

Doctors tell investment firm Leerink they don't anticipate upping their prescriptions of the new Ellipta line.

Five for things pharma marketers to know: Thursday, December 4

Five for things pharma marketers to know: Thursday, December 4

Despite drugmaker discount, VA still can't afford Sovaldi without additional funds; Ousted Sanofi CEO Viehbacher faces lawsuit for an alleged kickback scheme; GSK slims sales and R&D workforce.

Trial recruiting looks to tap online community leaders

Trial recruiting looks to tap online community leaders

CureClick, TrialReach and WEGO team to leverage health communities and speed trial recruitment.

Rx-opioid related deaths fall for the first time in 13 years

Rx-opioid related deaths fall for the first time in 13 years

The bad news: heroin-related deaths inched upwards.

FDA approves Amgen leukemia immunotherapy

Amgen's Blincyto was approved for a rare form of leukemia after receiving Breakthrough Therapy designation and a Priority Review.

Lilly nabs rights for osteoporosis patch

The drugmaker inked a deal with Zosano worth up to $440 million for the product, which is about to enter Phase-III in clinical trials.

Five things for pharma marketers to know: Wednesday, December 3

Five things for pharma marketers to know: Wednesday, December 3

An Italian court backs the anti-trust's stand that Novartis and Roche colluded in Lucentis marketing; AstraZeneca is the test case for the court's new interpretation of pay-for-delay; early-stage results prompt Biogen Idec to take its experimental Alzheimer's treatment to Phase-III.

Point-of-care messaging growth surpasses DTC growth: study

Point-of-care messaging growth surpasses DTC growth: study

As patients spend more time in waiting rooms where they are primed to learn about their health, POC promotions are becoming a more essential part of the marketing mix, researchers find.

High deductibles, costs keep patients away

High deductibles, costs keep patients away

More cost data for the file the latest data shows that up-front healthcare costs are prompting many patients to delay office visits.

Actavis launches generic of Intuniv

The first low-cost version of the Shire ADHD drug benefits as a first-filer.

Five things for pharma marketers to know: Tuesday, December 2

Five things for pharma marketers to know: Tuesday, December 2

Otsuka acquires Avanir; hackers target pharma; Novartis must give up nicotine patch to finalize GSK consumer deal.

Insulin pump approval sets up showdown with Medtronic

Insulin pump approval sets up showdown with Medtronic

The approval adds a second option to a category that Medtronic has had to itself since 2006.

Baxter files long-acting hemophilia A treatment with FDA

US filing in hand, the company expects to submit drug for EMA approval in 2016.

Gilenya fails to help primary progressive MS patients

Novartis released Phase-III study results Monday.

World AIDS day highlights awareness gaps

World AIDS day highlights awareness gaps

The number of new HIV cases has held steady since the 1990s. Researchers note it is progress of a sort, but that driving numbers down requires one basic step: testing, testing, testing.

Five things for pharma marketers to know: Monday, December 1

Five things for pharma marketers to know: Monday, December 1

GSK is set to announce US job cuts this week, sales reps are getting the axe in China, and the FDA has rejected Avanir's inhalable migraine medication.

At Work With: Jeffrey Wilks

At Work With: Jeffrey Wilks

President, Advertising, inVentiv Health

Adherence is in the behavior

Adherence is in the behavior

There needs to be a greater effort put into the issue of adherence. What can academia, providers, pharma and payers do to address this pressing need?

Private View: Visual Ads

Private View: Visual Ads

Who's calling who "murky"?

Who's calling who "murky"?

Once we venerated doctors. Now we question every dollar they make

Partner Forum: Is data the key to trial recruitment?

LabCorp's purchase of CRO Covance promises to open access to LabCorp's patient database for trial recruiting. Can this help resolve problems like the disparity of female representation and scarcity of subjects for studies?

Upward Move: Ruby Gadelrab

Upward Move: Ruby Gadelrab

Ruby Gadelrab. VP, commercial marketing, 23andMe

DDR on DTC: Tecfidera

DDR on DTC: Tecfidera

Tecfidera's visual pun fails to deliver Biogen's message

Washington Insider - Dec 2014

Washington Insider - Dec 2014

I come not to bury government but to praise it—at least the singular agency I know best: FDA

CROs: Trial Blazing

CROs: Trial Blazing

Running clinical trials remains one of Big Pharma's biggest headaches. But thanks to canny use of social media, gamification techniques and even text messages, CROs have revitalized and revolutionized the process. Barbara Peck explains

Programmatic buying stands to disrupt healthcare marketing

Programmatic buying stands to disrupt healthcare marketing

Programmatic ad buying hasn't exactly taken over the industry, but its approach has precipitated a paradigm shift, media experts say.

Read the complete December 2014 Digital Edition

Click the above link to access the complete Digital Edition of the December 2014 issue of MM&M, with all text, charts and pictures.

Drop seen in online posts about HIV infection: infographic

Drop seen in online posts about HIV infection: infographic

To mark the 27th annual World AIDS Day on Monday, Treato prepared an infographic showing patient insights about the ongoing fight against the disease. Among them: while posts about infection decreased last year, discussions about prevention more than doubled.

BMS proposed HCV therapy gets cold shoulder from regulators

BMS proposed HCV therapy gets cold shoulder from regulators

FDA issued a complete response letter on daclatasvir.

Insurer's maternity app rewards healthy behaviors

Insurer's maternity app rewards healthy behaviors

United Healthcare's Baby Blocks app seeks to become all-in-one hub for expectant moms and their babies.

FDA panel recommends against steroid injection warning

An advisory panel voted against adding warnings to steroid injection labels.

FDA takes issue with metatags

The agency sent a Warning Letter to three marketers over their use of metatags in search engine marketing tactics.

Five things for pharma marketers to know: Wednesday, November 26

Five things for pharma marketers to know: Wednesday, November 26

Tecfidera gets label change; Amgen and AstraZeneca report psoriasis Phase-III antibody results; JAMA study reinforces statin guidelines.

Bayer launches respiratory awareness contest

Bayer launches respiratory awareness contest

Encouraging competitors to take an artistic approach to "Breathless Moments," the competition is a first for Bayer, which is already working on next year's effort.

Novartis employee terminated for falsifications

The scientist is also banned from receiving federal funding.

Bayer looks to exit diabetes device business

The German firm positions to focus on pharma pipeline and animal health.

Valeant adds to dermatology portfolio

Onexton is a first-and-only drug combination for treating acne.

Five things for pharma marketers to know: Tuesday, November 25

Five things for pharma marketers to know: Tuesday, November 25

AstraZeneca and Ranbaxy pay-for-delay case marches on; FDA extends Novartis multiple myeloma Priority Review timeline; Endo pays $25 for testosterone nasal gel.

Sharecare scales up again with QualityHealth buy

Sharecare scales up again with QualityHealth buy

Complementary solutions to drive growth with health plans as well as pharma clients, companies say.

FDA tempers opioid approval impact

FDA tempers opioid approval impact

The Center for Drug Evaluation and Research's director says there is a need for new opioids and cuts off dosing comparisons between extended-release and immediate-release opioids.

Vancouver tests prescription heroin

The north-of-the-border solution comes amid climbing heroin abuse in the US.

India to reorg pharmaceutical agencies

The reason: coordination and effectiveness.

Five things for pharma marketers to know: Monday, November 24

Five things for pharma marketers to know: Monday, November 24

BioMarin to acquire Dutch biotech Prosensa; Woodcock says significant efficacy key to Breakthrough Therapy designation; Stryker considers $16 billion bid for UK devicemaker Smith and Nephew.

Five things for pharma marketers to know: Friday, November 21

Five things for pharma marketers to know: Friday, November 21

EMA revises its conflict of interest policy; AbbVie all-oral HCV combo drug receives positive EU recommendation; Merck may help NewLink Genetics scale production of its Ebola vaccine.

Sanofi offers glimpse of next-gen. insulin strategy

Sanofi offers glimpse of next-gen. insulin strategy

In a company-hosted seminar today, the Paris-based drugmaker gave investors a preview of the future of its diabetes franchise.

FDA approves abuse-deterrent Hysingla ER

The first approved hydrocodone formulated to discourage misuse raises a challenge to controversial Zohydro.

World projected to spend $1T on drugs in 2018

World projected to spend $1T on drugs in 2018

The IMS Institute for Healthcare Informatics notes that developed markets remain a key driver.

Five things for pharma marketers to know: Thursday, November 20

Five things for pharma marketers to know: Thursday, November 20

CRS asks if high prices are a tool to offset CMS rebates, the FDA adds another DTC study to its lineup, and the NIH proposes making more clinical trial data public.

Ariz. film, entertainment agency adds depth to Fingerpaint

Ariz. film, entertainment agency adds depth to Fingerpaint

With the purchase of Olson Communications, the agency aims to serve clients eager for expertise from outside the healthcare industry.

Rethinking Healthcare Communications Through the Prism of Rare Diseases

Rethinking Healthcare Communications Through the Prism of Rare Diseases

Success today is predicated on recognizing that every patient is different, every disease is different, every drug, every breakthrough and every cure is different.

Unsealed court documents shed light on opioid marketing

Drug makers favor big spending on speakers' events and doctor outreach.

Gilead buys priority voucher for $125M

The scoop means the maker of HCV drugs Harvoni and Sovaldi can give any drug an accelerated review time.

Five things for pharma marketers to know: Wednesday, November 19

Five things for pharma marketers to know: Wednesday, November 19

Sanofi vets Takeda, devicemaker CEO candidates; Shaq returns for IcyHot; Royalty Pharma buys royalties on Vertex's Kalydeco.


Does a health psychology approach hold the key to Rx adherence? In MM&M's latest Leadership Exchange Uncut eBook, industry stakeholders from the payer, provider, academic and pharma realms explore the "why" behind medicine taking. Access here.

Email Newsletters